Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Scott Med J ; : 369330241245730, 2024 May 06.
Article in English | MEDLINE | ID: mdl-38711311

ABSTRACT

INTRODUCTION: Studies in recent years have shown that ribosome-binding protein-1 (RRBP1) is expressed at high rates in many cancers and that it may be a potential prognostic biomarker. The objective of the present study is to determine the RRBP1 expression level in prostatic carcinoma and neighboring non-neoplastic prostate tissue, the relationship between its expression level with prognostic factors, and the role of RRBP1 in the development of prostate cancer. MATERIALS AND METHODS: The study included 45 patients who were diagnosed with prostatic carcinoma and underwent radical prostatectomy in our center between the years 2010 and 2021. Pathology reports were reviewed. Mann-Whitney U test was used for the comparison of RRBP1 and GADPH values of the cases (control and tumoral tissue) between the primary tumor stage (pT) and Gleason score (GS) groups. Hierarchical regression analysis was used to explain the effective variables in explaining the RRBP1 value of the research cases. RESULTS: According to the Mann-Whitney U test, mean and median RRBP1-T values of the cases with GS ≥ 8 were detected to be statistically significantly higher than the mean and median RRBP1-T values of the cases with GS < 8. CONCLUSION: We found out that RRBP1 was expressed at higher rates in patients with high GS and advanced-stage patients. This result indicated that RRBP1 expression may be important in predicting the prognosis of prostate carcinoma.

2.
Andrologia ; 54(8): e14481, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35610190

ABSTRACT

To quantitatively determine testicular tissue stiffness values using shear wave elastography (SWE) in males that have sickle cell anemia (SCA) and to evaluate the relationship between elastography results and semen analysis parameters and hormone levels. Fifty patients diagnosed with SCA and followed up in the hematology outpatient clinic were evaluated in the urology outpatient clinic as the study group. In addition, there were 88 patients without any SCA-related complaints in the control group. We compared these groups with respect to their values, spermiogram parameters, testicular volume, and SWE values. Among patients in the SCA group, 28% had impaired sperm parameters. When testicular elastography was assessed, the testicular volumes were materially lower in the SCA group in comparison to the control group [right testicular volume: 14.76 (12.77-18.12) and 19.68 (15.12-24.18), respectively, p < 0.001; left testicular volume: 14.11 (11.06-17.32) and 16.59 (13.38-20.13), respectively, p = 0.015]. Additionally, the left testis central stiffness and the left testis inferior stiffness were significantly higher in the SCA group (p < 0.001 and p = 0.014, respectively). The age and hydroxyurea use had a worse effect on sperm parameters in patients with SCA (odds ratio: -0.161 and -1.914, standard deviation: 0.071 and 0.921, and p = 0.024 and p = 0.038, respectively). We consider that the technique utilized in this study for SWE values is fast and can be adopted as a reliable diagnostic tool and follow-up practice in routine clinical practice to evaluate the acuteness of damage to the testicles in patients having SCA.


Subject(s)
Anemia, Sickle Cell , Elasticity Imaging Techniques , Anemia, Sickle Cell/complications , Anemia, Sickle Cell/diagnostic imaging , Elasticity Imaging Techniques/methods , Humans , Male , Prospective Studies , Semen , Testis/diagnostic imaging
3.
Int J Clin Pract ; 75(12): e14923, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34580970

ABSTRACT

BACKGROUND: TRUS biopsy is the preferred method for diagnosing prostate cancer, but it can cause infectious complications that arise with the contribution of fluoroquinolone resistance. We aimed to explore the potential protective effect of a second rectal enema before biopsy. METHODS: From January 2015 to December 2020, 419 patients were assessed retrospectively. Patients with a history of anticoagulant use, uncontrolled diabetes, urological surgery, prostate biopsy or recent hospitalisation or overseas travel, as well as those with the previous prostatitis, were excluded from the study. The patients were subsequently divided into two groups: Group 1 (n = 223) had received one enema, on the morning of the biopsy and Group 2 (n = 196) had received two, with the additional enema administered half an hour before the procedure. RESULTS: There was no significant difference between the groups in terms of age(P = .076), BMI (P = .489), diabetes (P = .265), prostate-specific antigen (PSA) level (P = .193), free/total PSA (f/t PSA) ratio (P = .518) and prostate size (P = .661) or in relation to cancer detection (P = .428). The median hospitalisation date was significantly higher in Group 1 (P = .003) as was urinary tract infection (UTI) development (P = .004). However, there was no significant difference in terms of fever and sepsis (P = .524 and P = .548, respectively). Additionally, subgroup analysis demonstrated that UTI was significantly lower in patients with diabetes mellitus who had received a second enema (P = .004), though there was no significant difference in UTI between the groups in those without diabetes mellitus (P = .215). Multivariable analysis showed that age and diabetes were significant risk factors for the development of UTI (OR: 1.074, 95% CI: 1.027-1.130, P = .002 and OR: 1.220, 95% CI: 0.131-0.665, P = .003, respectively). Furthermore, the second enema was a significant protective factor for preventing UTI (OR: -1.794, 95% CI: 2.208-16.389, P < .001). CONCLUSION: Older age and the presence of diabetes mellitus are independent risk factors for UTI after prostate biopsy. A second enema procedure before biopsy may protect patients from related infectious complications and could therefore be used as an alternative preventative method.


Subject(s)
Prostate , Prostatic Neoplasms , Aged , Biopsy , Enema , Humans , Male , Prostate/diagnostic imaging , Retrospective Studies , Ultrasonography, Interventional
4.
Andrology ; 9(4): 1119-1125, 2021 07.
Article in English | MEDLINE | ID: mdl-33686805

ABSTRACT

BACKGROUND: Obesity has been associated with severe conditions and sexual dysfunction. Bariatric surgery has effects positively patients' sexual function. OBJECTIVES: To assess the effect of bariatric surgery on sexual functions of couples. MATERIALS AND METHODS: The study included 57 obese patients and their sexually active partners. Male participations were assessed with the International Index of Erectile Function (IIEF) and Male Sexual Health Questionaries (MSHQ-4), and female participations were assessed with the Female Sexual Function Index (FSFI). RESULTS: There were 31 (54.4%) male patients and 26 (45.6%) female patients in the study. The median IIEF score of the male patients statistically increased postoperatively (p < 0.001). The IIEF subgroup areas were found to have increased after surgery. The median FSFI score of the female patients statistically increased postoperatively (p < 0.001). The median FSFI of male patients' partners significantly increased postoperatively (p < 0.001). All FSFI domains were statistically significantly increased (p < 0.001, all areas). The median IIEF value of the postoperative partners of the female patients also increased statistically significant (p < 0.001). In addition, the increases in the IIEF's subdomains in terms of sexual desire (p < 0.001), intercourse satisfaction (p < 0.001), and general satisfaction (p < 0.001) were statistically significant. CONCLUSION: The sexual functions of both males and females and also their' partners were improved after bariatric surgery. Patients with preoperative poor sexual function achieve significant benefits over patients without sexual dysfunction.


Subject(s)
Obesity/complications , Obesity/surgery , Sexual Behavior , Sexual Dysfunction, Physiological , Adult , Bariatric Surgery , Female , Humans , Male , Sexual Dysfunction, Physiological/etiology , Sexual Partners , Surveys and Questionnaires
5.
Int Urol Nephrol ; 47(7): 1099-103, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25947333

ABSTRACT

PURPOSE: To investigate renal function in idiopathic hypogonadotropic hypogonadic (IHH) patients by measuring glomerular filtration rate (GFR) using modification of diet in renal disease formula, and determine whether there is any relationship between GFR and testosterone levels. METHODS: Thirty-three patients with IHH and 37 healthy control subjects participated in this study. RESULTS: The IHH group showed statistically significant higher GFR and proteinuria with respect to the control group (163.1 ± 46.9 to 117.9 ± 30.5 mL/min, p < 0.001; 0.2 ± 0.1 to 0.08 ± 0.02 mg/dL, p = 0.041, respectively). Uric acid and creatinine levels were statistically lower than in the control group (4.6 ± 0.5-3.6 ± 0.9 mg/dL, p = 0.02; 0.7 ± 0.2 to 0.9 ± 0.2 mg/dL, p < 0.001, respectively). Hyperfiltration positively correlated with IHH in multivariate linear regression analyses (ß = 0.591, p < 0.001). In addition, in the IHH group, we found that the GFR increased independently of body mass index and age. CONCLUSION: Our study confirms that low testosterone in IHH patients is associated with glomerular hyperfiltration. Patients with IHH should be carefully monitored with respect to their GFR.


Subject(s)
Glomerular Filtration Rate , Hypogonadism , Renal Insufficiency , Testosterone/blood , Adolescent , Adult , Age Factors , Body Mass Index , Creatinine/blood , Humans , Hypogonadism/blood , Hypogonadism/complications , Male , Prognosis , Proteinuria/diagnosis , Proteinuria/etiology , Renal Insufficiency/blood , Renal Insufficiency/diagnosis , Renal Insufficiency/etiology , Risk Factors , Statistics as Topic
6.
Turk J Urol ; 39(1): 48-52, 2013 Mar.
Article in English | MEDLINE | ID: mdl-26328078

ABSTRACT

Formaldehyde is a chemical substance with a pungent odor that is highly soluble in water and occurs naturally in organisms. Formaldehyde, when taken into organisms, is metabolized into formic acid in the liver and erythrocytes and is then excreted, either with the urine and feces or via the respiratory system. Form-aldehyde is widely used in the industrial and medical fields, and employees in these sectors are frequently exposed to it. Anatomists and medical students are affected by formaldehyde gas during dissection lessons. Because full protection from formaldehyde is impossible for employees in industrial plants using this chemical and for workers in laboratory conditions, several measures can be implemented to prevent and/or reduce the toxic effects of formaldehyde. In this review, we aimed to identify the toxic effects of formaldehyde on the urinary system.

8.
Neurol Res ; 31(3): 313-5, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19036180

ABSTRACT

OBJECTIVE: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. METHOD: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). RESULTS: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. CONCLUSION: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors.


Subject(s)
Carbolines/adverse effects , Electroencephalography/drug effects , Erectile Dysfunction/drug therapy , Phosphodiesterase 5 Inhibitors , Phosphodiesterase Inhibitors/adverse effects , Carbolines/therapeutic use , Cohort Studies , Humans , Male , Middle Aged , Phosphodiesterase Inhibitors/therapeutic use , Tadalafil , Time Factors
9.
Urology ; 72(4): 743-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18554698

ABSTRACT

OBJECTIVES: To evaluate the effects of rolipram, a phosphodiesterase 4 enzyme inhibitor, on Escherichia coli-induced renal oxidative damage in an acute pyelonephritis (PYN) rat model. METHODS: A total of 35 male Wistar albino rats were randomly divided into 7 groups (n = 5) as follows: control (uninfected), PYN 24 hours, PYN 48 hours, PYN 72 hours, PYN + rolipram 24 hours, PYN + rolipram 48 hours, and PYN + rolipram 72 hours. Ascending PYN was induced in the study groups by E. coli inoculation into the bladder, and the urethras were then occluded by collodium for 4 hours. Rolipram injections (1 mg/kg) were started before bacterial inoculation and repeated at 24-hour intervals in the PYN + rolipram groups until death. The rats were killed at the indicated times. Malondialdehyde and nitric oxide levels and superoxide dismutase and catalase activities were determined in kidney homogenates. Histopathologic examinations were also performed. RESULTS: Tissue malondialdehyde and nitric oxide levels and superoxide dismutase and catalase activities were significantly increased in the kidneys from the PYN groups. However, rolipram administration reduced renal malondialdehyde and nitric oxide levels and enhanced superoxide dismutase and catalase activities. The histopathologic examinations demonstrated that rolipram treatment reduced the inflammation grade in the kidney specimens. CONCLUSIONS: The results of our study have shown that rolipram has a protective effect on renal tissue from E. coli-induced oxidative injury. Therefore, phosphodiesterase 4 inhibitors might be a novel therapeutic option for the prevention and/or management of acute PYN.


Subject(s)
Phosphodiesterase 4 Inhibitors , Phosphodiesterase Inhibitors/therapeutic use , Pyelonephritis/prevention & control , Rolipram/therapeutic use , Acute Disease , Animals , Disease Models, Animal , Kidney/metabolism , Male , Oxidation-Reduction , Pyelonephritis/metabolism , Rats , Rats, Wistar
10.
J Clin Ultrasound ; 36(3): 148-52, 2008.
Article in English | MEDLINE | ID: mdl-18088054

ABSTRACT

PURPOSE: To investigate the long-term effect of varicocele repair on ipsilateral intratesticular arterial resistance index (RI) using color Doppler sonography (CDS). METHODS: A total of 26 infertile patients with left varicocele who underwent a testicular artery and lymphatic-sparing subinguinal varicocelectomy were examined with CDS for intratesticular flow parameters before and at least 6 months after surgery. We also evaluated preoperative and postoperative semen parameters. RESULTS: The mean values of RI, end-diastolic velocity and pulsatility index decreased significantly after surgery, whereas no significant change was observed in peak systolic velocity. Repair of the varicocele resulted in a statistically significant increase in the total sperm count, motility, morphology, and total motile sperm count. However, no significant correlation was found between sperm parameters and RI values (p > 0.05). CONCLUSIONS: Our data show that a significant improvement occurs in testicular blood supply and sperm parameters after surgical varicocele repair, without significant correlation between these 2 changes.


Subject(s)
Testis/blood supply , Testis/diagnostic imaging , Varicocele/surgery , Vascular Resistance , Adult , Arteries , Follow-Up Studies , Humans , Male , Postoperative Period , Sperm Count , Sperm Motility , Time , Treatment Outcome , Ultrasonography, Doppler, Color
11.
J Clin Anesth ; 19(8): 587-90, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18083471

ABSTRACT

STUDY OBJECTIVE: To determine whether intravenous injection of lornoxicam 30 minutes before skin incision provides better pain relief after varicocelectomy than postoperative administration of lornoxicam. DESIGN: Prospective, double-blind, randomized clinical investigation. SETTING: Operating room and postoperative recovery area. PATIENTS: 44 ASA physical status I and II adult male patients undergoing varicocelectomy. INTERVENTIONS: Patients were randomized either to receive 8 mg lornoxicam infusion 30 minutes before skin incision, followed by saline infusion immediately after skin closure (group 1), or to receive the identical injections but in reverse order (group 2). All patients received local anesthesia with bupivacaine. MEASUREMENTS: Postoperative pain scores were evaluated hourly for the first 8 hours after surgery, then at 12, 16, 20, and 24 hours after surgery, using a 10-cm visual analog scale. Time to first analgesic request and patients' global assessments also were recorded. MAIN RESULTS: Patients in group 1 reported significantly lower pain scores (P < 0.05) at all time intervals except at 24 hours and better global assessment (P = 0.001) than did group 2. There were significantly fewer patients in the preemptive group than group 2 who required rescue analgesic within the first 24 hours (0% vs 22.7%; P = 0.024). Mean time to first analgesic request was also significantly longer in the preemptive group (P = 0.001). CONCLUSION: Intravenous lornoxicam administered before surgery has a better analgesic effect for varicocelectomy than when administered postoperatively.


Subject(s)
Analgesia/methods , Pain, Postoperative/drug therapy , Piroxicam/analogs & derivatives , Postoperative Care/methods , Preoperative Care/methods , Varicocele/surgery , Adult , Ambulatory Surgical Procedures/methods , Anesthesia, Local/methods , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Double-Blind Method , Humans , Injections, Intravenous , Male , Pain Measurement/statistics & numerical data , Pain, Postoperative/prevention & control , Piroxicam/administration & dosage , Piroxicam/therapeutic use , Prospective Studies , Sodium Chloride/administration & dosage , Time Factors , Treatment Outcome
12.
Urol Int ; 79(4): 297-301, 2007.
Article in English | MEDLINE | ID: mdl-18025845

ABSTRACT

INTRODUCTION: To evaluate the effects of periprostatic bupivacaine administration on pain control and analgesic consumption after transurethral prostate resection (TURP). MATERIALS AND METHODS: The study included 40 male patients with benign prostatic hyperplasia who underwent TURP, and they were divided randomly into two groups. All patients were operated under general anesthesia. The study group patients (n = 20) received periprostatic bupivacaine (0.5% 20 ml) injection (group I), and the control patients (n = 20) received only saline (NaCl 0.9% 20 ml) injection (group II). All injections were performed bilaterally into the periprostatic areas immediately after the TURP procedure via the transperineal route. In the postoperative period, all patients (groups I and II) received tramadol using a patient-controlled analgesia device. Postoperative pain was assessed and recorded using the visual analog scale (VAS) at postoperative hours 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 20, 24, and 48. Total tramadol consumptions and additional analgesic requirements were also recorded and compared between groups. RESULTS: There was no difference in demographic data between the two groups (p > 0.05). VAS scores of the patients at hours 1, 3, 4, 5, 7, 8, and 12 were found to be significantly lower in group I than in group II (p < 0.05). Total tramadol consumption and patient-controlled analgesia demands of groups I and II were 153.5 +/- 52.4 vs. 465.0 +/- 55.1 mg and 17.1 +/- 7.7 vs. 77.8 +/- 7.5 mg, respectively (p < 0.001). No side effect was observed regarding bupivacaine injections. CONCLUSIONS: Periprostatic bupivacaine administration was a useful and safe method for postoperative pain control and reduced analgesic consumption in patients undergoing TURP.


Subject(s)
Anesthetics, Local/administration & dosage , Bupivacaine/administration & dosage , Nerve Block/methods , Pain, Postoperative/prevention & control , Prostatic Hyperplasia/surgery , Aged , Dose-Response Relationship, Drug , Humans , Male , Middle Aged , Pain Measurement , Pain, Postoperative/physiopathology , Probability , Prostate/drug effects , Prostate/innervation , Prostatic Hyperplasia/pathology , Reference Values , Sensitivity and Specificity , Statistics, Nonparametric , Transurethral Resection of Prostate/adverse effects , Transurethral Resection of Prostate/methods , Treatment Outcome
13.
Basic Clin Pharmacol Toxicol ; 100(5): 328-33, 2007 May.
Article in English | MEDLINE | ID: mdl-17448119

ABSTRACT

The objective of this study was to compare the beneficial effects of caffeic acid phenethyl ester (CAPE), vitamin C, vitamin E and N-acetylcysteine on vancomycin-induced nephrotoxicity. Thirty rats were randomly devided into six groups: (i) control; (ii) vancomycin, 200 mg/kg administrated via intraperitoneal route; (iii) vancomycin plus CAPE-vancomycin with 10 micromol/kg CAPE; (iv) vancomycin plus vitamin C-vancomycin (intraperitoneally) with 200 mg/dl vitamin C in drinking water; (v) vancomycin plus vitamin E-vancomycin with 1000 mg/kg body weight vitamin E (intramuscularly); and (vi) vancomycin plus N-acetylcysteine-vancomycin with 10 mg/kg body weight (intraperitoneally) of N-acetylcysteine. Vancomycin treatments were started 1 day after the first administrations of these agents and continued for 7 days. At the end of the experiments, catalase activity was significantly decreased by vancomycin in kidney homogenates (P < 0.05). Vitamin E, vitamin C, N-acetylcysteine and CAPE administrations decreased the blood urea nitrogen levels increased by vancomycin, although significant differences were detected only in the vitamins E and C groups (P < 0.05). Increased renal malondialdehyde and nitric oxide levels by vancomycin were significantly suppressed by agents used in the study (P < 0.05). Histopathological examination demonstrated prominent damages in the vancomycin-treated group. Vitamin E was the most beneficial agent on vancomycin-induced tubular damage, followed by vitamin C, N-acetylcysteine and CAPE treatments, respectively. The data suggest that vitamin E, as well as vitamin C, N-acetylcysteine and CAPE, could be useful for reducing the detrimental effects on vancomycin-induced toxicity in kidneys.


Subject(s)
Acetylcysteine/pharmacology , Ascorbic Acid/pharmacology , Caffeic Acids/pharmacology , Kidney Diseases/prevention & control , Phenylethyl Alcohol/analogs & derivatives , Vancomycin/toxicity , Vitamin E/pharmacology , Animals , Anti-Bacterial Agents/toxicity , Antioxidants/pharmacology , Blood Urea Nitrogen , Catalase/metabolism , Disease Models, Animal , Drinking , Drug Combinations , Injections, Intramuscular , Injections, Intraperitoneal , Kidney/drug effects , Kidney/enzymology , Kidney/pathology , Kidney Diseases/chemically induced , Kidney Diseases/pathology , Male , Phenylethyl Alcohol/pharmacology , Rats , Rats, Wistar , Water Supply
14.
J Ultrasound Med ; 26(5): 601-4, 2007 May.
Article in English | MEDLINE | ID: mdl-17460002

ABSTRACT

OBJECTIVE: The purpose of this study was to investigate the incidence of the retroaortic left renal vein (RLRV) in patients with varicocele. METHODS: The left renal vein was ultrasonographically investigated for the presence of the RLRV in 140 patients with varicocele and a control group of 137 age-matched patients. The main diagnostic criteria for varicocele were the presence of a varicose vein with a diameter of 3 mm or larger at rest and with a reflux lasting more than 2 seconds during the Valsalva maneuver. The RLRV was defined as a posterior course of the left renal vein to the aorta at the level of the origin of the superior mesenteric artery. RESULTS: The RLRV was observed in 13 (9.3%) of the 140 patients with varicocele and 3 (2.2%) of the control patients. The incidence of the RLRV was found to be significantly higher in patients with varicocele compared with the control patients (P = .018, Fisher exact test). In 13 patients with the RLRV, left varicocele and bilateral varicocele were detected in 10 and 3 cases, respectively. CONCLUSIONS: In this study, the incidence of the RLRV was found to be significantly higher in patients with varicocele compared with control patients. Thus, we suggest that the presence of the RLRV may be considered one of the etiologic factors in the development of varicocele.


Subject(s)
Aorta, Abdominal/abnormalities , Aorta, Abdominal/diagnostic imaging , Renal Veins/abnormalities , Renal Veins/diagnostic imaging , Risk Assessment/methods , Varicocele/diagnostic imaging , Varicocele/epidemiology , Adolescent , Adult , Case-Control Studies , Humans , Incidence , Male , Middle Aged , Risk Factors , Turkey/epidemiology , Ultrasonography
15.
Mol Cell Biochem ; 297(1-2): 131-8, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17051318

ABSTRACT

Although oxidative damage is known to be involved in inflammatory-mediated tissue destruction, modulation of oxygen free radical production represents a new approach to the treatment of inflammatory diseases. Caffeic acid phenethyl ester (CAPE), an active component of propolis from honeybee hives, has antioxidant, anti-inflammatory and antibacterial properties. For that reason, we aimed to investigate the efficiency of CAPE administration in preventing oxidative damage in pyelonephritis (PYN) caused by Escherichia coli. In this study, 35 Wistar rats were grouped as follows: control, PYN 24 h, PYN 48 h, PYN 72 h, CAPE 24 h, CAPE 48 h and CAPE 72 h. E. coli (1 x 10(9) c.f.u.) were inoculated into the rats in both PYN and CAPE groups via urethral catheterization. Ten microM/kg-body weight CAPE was injected to the rats in all CAPE groups 24 h before E. coli infection, and injections were repeated at 24-h intervals. Rats were sacrificed 24 h, 48 h and 72 h after infection in both PYN and CAPE groups. Malondialdehyde (MDA) and nitric oxide (NO) levels were significantly increased in kidneys of PYN groups. The activities of the antioxidant enzymes, catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and xanthine oxidase (XO) were also elevated by E. coli. However, CAPE administration reduced MDA and NO levels, as well as XO activity, although it increased SOD and GSH-Px activities. Histopathological examination showed that CAPE reduced the inflammation grade induced by E. coli. In conclusion, CAPE administrations decrease the oxidative damage occurring in PYN and therefore could be used for medical management of bacterial nephropathy.


Subject(s)
Caffeic Acids/pharmacology , Escherichia coli/physiology , Oxidative Stress/drug effects , Phenylethyl Alcohol/analogs & derivatives , Pyelonephritis/metabolism , Animals , Catalase/metabolism , Glutathione Peroxidase/metabolism , Inflammation , Kidney/drug effects , Kidney/pathology , Male , Malondialdehyde/metabolism , Nitric Oxide/metabolism , Phenylethyl Alcohol/pharmacology , Pyelonephritis/chemically induced , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Xanthine Oxidase/metabolism
16.
Pharmacol Res ; 54(4): 293-7, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16887363

ABSTRACT

Testicular torsion causes an enhanced formation of reactive oxygen species which contributes to the pathophysiology of ischemia-reperfusion injury in the testis. We evaluated here the effect of caffeic acid phenethyl ester (CAPE), a new antioxidant and anti-inflammatory agent on histopathological changes in testicular ischemia-reperfusion injury. Adult male Wistar rats were divided into six groups of five each: control group 1 (n=5), sham operation group 2 (n=5), torsion/detorsion (T/D) group 3 (n=5), T/D+saline group 4 (n=5), T/D+CAPE group 5 (n=5) and T/D+CAPE group 6 (n=5). Group 1 served to determine baseline values of histopathological parameters, group 2 animals that underwent sham operation served as a control, while groups 3-6 animals were subjected to left unilateral torsion (2 h) and detorsion (24 h) periods. All the groups were sacrified 24 h later except group 6. CAPE was injected 2 days with the same dose to the group 6 and it was sacrified 48 h later. One testis removed and fixed in Bouin's solution. After routine tissue processing myeloperoxidase (MPO) and inducible nitric oxide synthase (iNOS) immunohistochemical methods were studied from paraffin embedded tissues. Treating rats with CAPE (applied at 10 micromol/kg, 30 min prior to T/D) attenuated the testicular injury and as well as the tissue levels of MPO. At the same time testis tissue showed a decrease in iNOS activity. Our results suggest that CAPE treatment have a protective role on testicular T/D and this effect may be due to inhibiting the neutrophil mediated cellular injury.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antioxidants/pharmacology , Caffeic Acids/pharmacology , Phenylethyl Alcohol/analogs & derivatives , Reperfusion Injury/drug therapy , Testis/pathology , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Antioxidants/administration & dosage , Caffeic Acids/administration & dosage , Immunohistochemistry , Injections, Intraperitoneal , Male , Nitric Oxide Synthase Type II/metabolism , Peroxidase/metabolism , Phenylethyl Alcohol/administration & dosage , Phenylethyl Alcohol/pharmacology , Rats , Rats, Wistar , Regional Blood Flow/physiology , Reperfusion Injury/pathology , Spermatic Cord Torsion/drug therapy , Spermatic Cord Torsion/pathology , Testis/blood supply
17.
Int J Pediatr Otorhinolaryngol ; 70(11): 1919-22, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16901550

ABSTRACT

OBJECTIVE: To determine any possible adverse effect of 1-deamino 8-D-arginine vasopressin (DDAVP) spray on nasal cytology and mucociliary clearance in patients with nocturnal enuresis. METHODS: Twenty-two children aged 6-16 enrolled in the study. Epithelial surface cells samples were taken from the nasal mucosa and mucociliary clearance time was calculated before and 1 and 6 months after administration of DDAVP spray. RESULTS: No qualitative changes in the epithelial surface cells and mucociliary clearance time were observed at 1 and 6 months after therapy. CONCLUSION: Based on the findings of the present study, DDAVP spray can be used for 6 months in children without apparent risk of damage to the epithelial surface cells and mucociliary clearance time.


Subject(s)
Antidiuretic Agents/adverse effects , Deamino Arginine Vasopressin/adverse effects , Mucociliary Clearance/drug effects , Nasal Mucosa/drug effects , Nocturnal Enuresis/drug therapy , Administration, Intranasal , Adolescent , Antidiuretic Agents/administration & dosage , Antidiuretic Agents/therapeutic use , Child , Cilia/drug effects , Cilia/ultrastructure , Deamino Arginine Vasopressin/administration & dosage , Deamino Arginine Vasopressin/therapeutic use , Female , Humans , Male , Nasal Mucosa/ultrastructure
18.
Cell Biochem Funct ; 23(3): 151-5, 2005.
Article in English | MEDLINE | ID: mdl-15386530

ABSTRACT

This study was designed to investigate the effect of L-carnitine in ischaemia and reperfusion of the rat kidney. Rats were randomly allocated into three groups. Group I (control group; n = 6) received no treatment. Group II (isotonic saline group; n = 6), received 2 ml of isotonic saline 15 min before the renal ischaemia, and group III (carnitine group; n = 6) received L-carnitine hydrochloride (100 mg kg(-1)) intraperitoneally. At the end of the reperfusion period, rats were sacrificed. Tissue malondialdehyde level (MDA), myeloperoxidase (MPO) activity, and nitrite/nitrate (NO) level of renal tissue were measured to evaluate the lipid peroxidation, neutrophil function, and nitric oxide metabolism, respectively. The tissue levels of MDA, MPO and NO were lower in group III (71.8 +/- 8.4, 172.1 +/- 27.4 U g(-1) tissue, 76.3 +/- 29.7 micromol l(-1) respectively) than levels in groups I (103.4 +/- 13.4 nmol g(-1), 325.9 +/- 20.2 U g(-1) tissue, 144.5 +/- 39.2 micromol l(-1), respectively) and II (103.5 +/- 11.4 nmol g(-1), 317.1 +/- 41.5 U g(-1) tissue, 148.9 +/- 23.9 micromol l(-1), respectively). It is shown that carnitine protects kidney tissue against ischaemia-reperfusion injury.


Subject(s)
Carnitine/pharmacology , Kidney Diseases/drug therapy , Reperfusion Injury/drug therapy , Animals , Kidney Diseases/metabolism , Lipid Peroxidation/drug effects , Nitric Oxide/metabolism , Peroxidase/metabolism , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Reperfusion Injury/metabolism
19.
Scand J Urol Nephrol ; 38(5): 391-5, 2004.
Article in English | MEDLINE | ID: mdl-15764250

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the intensity of lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH) with and without diabetes. We also determined whether alpha1-blockers improve subjective and objective symptoms similarly in these patients. MATERIAL AND METHODS: The study subjects comprised 281 patients (60 with diabetes and 221 non-diabetics with clinically diagnosed BPH) who were treated with alpha1-blockers (doxazosin, terazosin, alfuzosin and tamsulosin). The international prostate symptom score (IPSS), bother score, maximum flow rate (Q(max)) and post-void residual urine volume (PVR) were determined at baseline and after treatment for a minimum of 6 months. RESULTS: Diabetic patients had a lower baseline Q(max) than non-diabetics (p < 0.001), while the IPSS, bother score and PVR did not differ significantly between the two groups. After treatment with alpha1-blockers, lower urinary tract symptoms improved significantly. The improvement rates of the IPSS and bother score were significantly higher in the diabetic patients than in the non-diabetics (p < 0.01). The relationship between the duration of diabetes and the effect of alpha1-blockers on IPSS, bother score, Q(max) and PVR was not statistically significant (p > 0.05). CONCLUSIONS: The voiding function of the bladder may be more affected by diabetes than the storage function in patients with BPH. Treatment with alpha1-blockers appears to be useful for diabetic patients with BPH and its effectiveness is not altered by the duration of diabetes.


Subject(s)
Adrenergic alpha-Antagonists/therapeutic use , Diabetes Mellitus/diagnosis , Prazosin/analogs & derivatives , Prostatic Hyperplasia/drug therapy , Urination Disorders/diagnosis , Aged , Aged, 80 and over , Cohort Studies , Doxazosin/therapeutic use , Follow-Up Studies , Humans , Male , Middle Aged , Prazosin/therapeutic use , Probability , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/diagnosis , Quinazolines/therapeutic use , Reference Values , Retrospective Studies , Risk Assessment , Severity of Illness Index , Sulfonamides/therapeutic use , Tamsulosin , Treatment Outcome , Urination Disorders/complications , Urodynamics
SELECTION OF CITATIONS
SEARCH DETAIL
...